A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Trial Profile

A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Sponsors Ardelyx
  • Most Recent Events

    • 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
    • 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
    • 09 Aug 2017 Results from this trial are expected in the fourth quarter of 2017, according to an Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top